General Myelodysplastic Syndrome

Revlimid® Reduces Need for Blood Transfusions in Some Myelodysplastic Syndromes (08-31-2016)

The agent Revlimid (lenalidomide) reduces the need for blood transfusions among patients with lower-risk, non-del (5q) myelodysplastic syndromes who are dependent upon red blood cell transfusions, but are not eligible for erythropoiesis-stimulating agents.... Continue Reading

Myeloablative Treatment Regimens Superior to Reduced Intensity Treatment for AML and MDS Patients Undergoing Stem Cell Transplant (12-30-2015)

Hematopoietic Stem Cell Transplant (SCT) is a standard and potentially curative treatment for individuals with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). Historically only high dose myeloablative treatment regimens were utilized since... Continue Reading

Exposure to Some Inflammatory Bowel Disease Drugs May Increase Leukemia Risk (08-8-2014)

Thiopurines are an established treatment for inflammatory bowel disease (IBD) patients.  They are used to reduce inflammation and provide symptom relief.  Thiopurine immunosuppressive drugs have now been reported to increase the risk of acute myelod... Continue Reading

Aspirin Continues to Look Promising for Cancer Prevention (03-26-2012)

A combined analysis of 51 randomized trials found that daily aspirin use reduces the risk of new cancer diagnoses as well as the risk of cancer death. These results were published in The Lancet. A growing body of evidence suggests that aspirin may reduce... Continue Reading

Stay on Top of Your Family History of Cancer (07-15-2011)

People who are at high risk of cancer as a result of their family history may be advised to undergo earlier or more intensive cancer screening. Because family history of cancer can change over time, it’s important to update this information periodically... Continue Reading

Regular Use of Acetaminophen May Increase Risk of Blood Cancers (05-13-2011)

Long-term, regular use of acetaminophen (Tylenol®) may increase the risk of leukemia and lymphoma. These results were published in the Journal of Clinical Oncology. Some studies have suggested that use of aspirin and other nonsteroidal anti-inflammatory... Continue Reading

Vidaza® Improves Survival in Higher-risk Myelodysplastic Syndromes (03-6-2009)

According to the results of a Phase III clinical trial, treatment with Vidaza® (azacitidine) results in better survival than conventional care among patients with higher-risk myelodysplastic syndromes (MDS). These results were published in Lancet Oncology. Myelodysplastic... Continue Reading

The American Society of Clinical Oncology 2008: Highlights of Treatment of Hematological Malignancies (01-30-2009)

The American Society of Clinical Oncology 2008: Highlights of Treatment of Hematological Malignancies The 2008 annual meeting of the American Society of Clinical Oncology (ASCO), held in Chicago, Illinois, again revealed advances in the treatment of... Continue Reading

New Risk Model for MDS Applies to All Stages of Disease (12-31-2008)

New Risk Model for MDS Applies to All Stages of Disease A new risk model for myelodysplastic syndrome (MDS) provides survival projections for all stages of the disease and has proven superior to the International Prognostic Scoring System (IPSS) that... Continue Reading

Older Age Does Not Affect Survival in Patients with AML or MDS Who Undergo Mini-transplants (12-30-2008)

Older Age Does Not Affect Survival in Patients with AML or MDS Who Undergo Mini-transplants Age should not be a barrier for non-myeloablative allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome... Continue Reading

Next Page »